IPAX-1 (TLX101 for Glioblastoma Therapy) Clinical Trial Update
Telix announces preliminary safety data from the IPAX-1 Ph I/II study, with a follow-on study being planned in front-line therapy.
Telix Update on FDA New Drug Application Review for Illuccix®
Telix announces participation in a late-cycle meeting with the U.S. FDA regarding the ongoing review of the NDA for its prostate cancer imaging investigational product Illuccix®.
Telix Pharmaceuticals and Applied Radiology launch TelixU Medical Education Platform Focused on Radiopharmaceutical Research
Telix is pleased to announce the launch of TelixU, a new educational platform focused on radiopharmaceutical research in partnership with leading medical imaging journal, Applied Radiology.
Scott Law joins Telix as SVP Global Manufacturing Operations
Telix is delighted to announce that Scott Law has joined the Company as Senior Vice President, Global Manufacturing Operations.
Telix and ATS Awarded $1.56M ‘Eurostars’ Grant for Alpha Therapy
Advanced Nuclear Medicine Ingredients S.A, a wholly owned European subsidiary of Telix, and Alpha Therapy Solutions announce €990K (A$1.56M) ‘Eurostars-2’ research grant from the EUREKA Association.
Telix Symposium at SNMMI 2021 Virtual Annual Meeting
Telix is pleased to announce we will be presenting at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Virtual Annual Meeting to be held 11 – 15 June.
Telix and Eckert & Ziegler Sign US Co-Promotion Agreement for Prostate Cancer Imaging
Telix announces co-promotion agreement with EZAG for Telix’s investigational prostate cancer imaging product Illuccix® and EZAG’s GalliaPharm® gallium-68 generator.
Telix to Present at the 2021 Jefferies Virtual Healthcare Conference
Telix is pleased to announce that Chief Executive Officer, Dr. Christian Behrenbruch, will present at the Jefferies Virtual Healthcare Conference 2021.
Cardinal Health and Telix Launch Gallium Awareness Campaign
In collaboration with Cardinal Health, Telix is pleased to announce the launch of a gallium awareness campaign with the release of an in-depth white-paper entitled: “Moving beyond the Myth”.
TLX66 Meets Study Objectives in Patients with AL Amyloidosis
Telix announces bone marrow conditioning investigational candidate TLX66 has met study objectives, demonstrating the initial safety profile in patients with AL amyloidosis.